Alector, Inc.

NASDAQ (USD): Alector, Inc. (ALEC)

Last Price

3.63

Today's Change

-0.215 (5.58%)

Day's Change

3.60 - 3.84

Trading Volume

503,156

Overview

Market Cap

355 Million

Shares Outstanding

97 Million

Avg Volume

567,001

Avg Price (50 Days)

5.07

Avg Price (200 Days)

5.41

PE Ratio

-2.13

EPS

-1.71

Earnings Announcement

25-Feb-2025

Previous Close

3.85

Open

3.84

Day's Range

3.602 - 3.84

Year Range

3.602 - 8.9

Trading Volume

503,156

Price Change Highlight

1 Day Change

-5.58%

5 Day Change

-27.45%

1 Month Change

-21.15%

3 Month Change

-31.29%

6 Month Change

-32.56%

Ytd Change

-54.51%

1 Year Change

-23.95%

3 Year Change

-82.39%

5 Year Change

-77.04%

10 Year Change

-79.81%

Max Change

-79.81%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment